Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
Data to be presented at the 2022 AACR annual meeting highlights the unique nature of post-chemotherapy derived gene expression signatures in stratifying patient outcomes
Colorectal Cancer Screening is now translated into multiple languages to help people worldwide understand why, when and how to screen for colorectal cancer
If approved in the European Union, Fruquintinib will be the first novel targeted therapy for Metastatic Colorectal Cancer regardless of biomarker status in over a decade
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
Acquisition enhances Freenome's product portfolio, including autoantibody platform with additional biomarkers important in cancer detection
NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China
Launch of the Da Vinci Xi Robotic System is the highlight of the Robotic Colorectal Cancer Symposium organized with the Association of Colon and Rectal Surgeons of India
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)